Cellectis S.A. (NASDAQ:CLLS) and Harpoon Therapeutics Inc. (NASDAQ:HARP), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	21.43M	36.50	78.69M	-2.11	0.00
Harpoon Therapeutics Inc.	4.75M	57.13	27.37M	-0.94	0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Cellectis S.A. and Harpoon Therapeutics Inc.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-367.20%	-23%	-18.8%
Harpoon Therapeutics Inc.	-576.21%	0%	0%

Liquidity

Cellectis S.A.’s Current Ratio is 11.2 while its Quick Ratio is 11.2. On the competitive side is, Harpoon Therapeutics Inc. which has a 3.8 Current Ratio and a 3.8 Quick Ratio. Cellectis S.A. is better positioned to pay off short and long-term obligations compared to Harpoon Therapeutics Inc.

Analyst Ratings

Cellectis S.A. and Harpoon Therapeutics Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	2	1	2.33
Harpoon Therapeutics Inc.	0	0	2	3.00

Cellectis S.A.’s average target price is $35.25, while its potential upside is 88.40%. Harpoon Therapeutics Inc. on the other hand boasts of a $23.5 average target price and a 110.76% potential upside. The information presented earlier suggests that Harpoon Therapeutics Inc. looks more robust than Cellectis S.A. as far as analyst belief.

Insider & Institutional Ownership

Institutional investors held 29.4% of Cellectis S.A. shares and 35.2% of Harpoon Therapeutics Inc. shares. Comparatively, 0.5% are Harpoon Therapeutics Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
Harpoon Therapeutics Inc.	18.45%	0%	0%	0%	0%	26%

For the past year Cellectis S.A. has weaker performance than Harpoon Therapeutics Inc.

Summary

On 8 of the 12 factors Harpoon Therapeutics Inc. beats Cellectis S.A.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.